

Reference: FOI.ICB-2627/011

Subject: APMOC/Joint Formulary Discussions (Liothyronine & Low-Value Medicines)

I can confirm that the ICB does hold the information requested; please see responses below:

QUESTION	RESPONSE
<p>1. Meeting Minutes: All minutes, action logs, and briefing papers from APMOC and the Joint Formulary Group meetings held between January 2019 and the 31st December 2021 where the following were discussed:</p> <ul style="list-style-type: none"> ○ Liothyronine (T3) prescribing. ○ The Regional Medicines Optimisation Committee (RMOC) ○ The "Items which should not routinely be prescribed in primary care" policy 	<p>Please find enclosed requested information.</p> <p>Please note that FOI requests and responses are publicly available and therefore personal information has been redacted. The ICB considers the names included in the enclosed document(s) to be personal information and therefore has applied a section 40 (Personal Information) exemption to this information.</p> <p>BNSSG ICB has exempted one document from disclosure as this document contained patient information including numbers of patients per GP Practice and their health conditions.</p>
<p>2. Correspondence: Any internal correspondence (emails or memos) between the Medicines Optimisation Team and the APMOC members regarding the above in the same time period.</p>	<p>Please find enclosed correspondence.</p> <p>Please note that FOI requests and responses are publicly available and therefore personal information has been redacted. The ICB considers the names included in the enclosed document(s) to be personal information and therefore has applied a section 40 (Personal Information) exemption to this information.</p>

The information provided in this response is accurate as of 15 May 2026 and has been approved for release by Dr Ananthakrishnan Raghuram, Chief Clinical Leadership and Delivery Officer (Medical) for NHS Bristol, North Somerset and South Gloucestershire ICB.

BNSSG Joint Formulary Group Meeting

Meeting Held on: Tuesday 23rd July 2019
 Time: 09:30am – 12:30pm
 Venue: Southmead Hospital - Seminar Room

Minutes

Present:

[Redacted] (Chair) [Redacted] [Redacted] [Redacted] [Redacted] (Minutes) [Redacted] [Redacted] [Redacted] [Redacted]	[Redacted] Principal Medicines Optimisation Pharmacist, (BNSSG) [Redacted] Pharmacy Manager Principal Pharmacist, UHB [Redacted] GP Clinical Lead in Prescribing for BNSSG CCG [Redacted] Interface Pharmacist, BNSSG CCG [Redacted] Medicines Optimisation Pharmacist, AWP NHS Trust [Redacted] Team Administrator & Minute Taker, BNSSG CCG [Redacted] Commissioning Policy Development Manager, BNSSG CCG [Redacted] Interface Pharmacist, BNSSG CCG [Redacted] Rotational Pharmacist, NBT [Redacted] Formulary Pharmacist, NBT [Redacted] GP, North Somerset
--	--

Apologies:

[Redacted] [Redacted] [Redacted] [Redacted] [Redacted] [Redacted]	[Redacted] Deputy Director (Medicines Optimisation), BNSSG CCG [Redacted] Deputy Lead Pharmacist, Weston General Hospital [Redacted] Public Health Consultant, Bristol City Council [Redacted] Head Pharmacy Services, Offender Health, BCH [Redacted] Principal Medicines Optimisation Pharmacist, BNSSG CCG [Redacted] Formulary and Interface Pharmacist, NBT
--	---

1 Welcome, Introduction, Apologies & Declarations of Interest

[Redacted] [Redacted]
 [Redacted] There were no declarations of interest recorded. It was discussed that the meeting was not quorate as there was no consultant representation. Any decisions agreed in principle today, will have to be ratified by email.

[Redacted]
 [Redacted]

[Redacted] [Redacted]
 [Redacted] [Redacted]
 [Redacted]

[Redacted]

- [Redacted]
- [Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]		
[REDACTED]		
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[Redacted text block]

[Redacted text block]

- | [Redacted list item]
- | [Redacted list item]
- | [Redacted list item]
- | [Redacted list item]
- | [Redacted list item]
- | [Redacted list item]
- | [Redacted list item]
- | [Redacted list item]
- | [Redacted list item]
- | [Redacted list item]
- | [Redacted list item]

[Redacted text block]

[Redacted text block]

[Redacted text block]

- [Redacted list item]
- [Redacted list item]

[Redacted text block]

[Redacted text block]

[REDACTED]

[REDACTED]

[REDACTED]

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

- [REDACTED]
- [REDACTED]

when this has been established.

[Redacted]

[Redacted]

[Redacted]

- [Redacted]
- [Redacted]
- [Redacted]
- [Redacted]
- [Redacted]
- [Redacted]
- [Redacted]
- [Redacted]
- [Redacted]
- [Redacted]

[Redacted]

[REDACTED]

- [REDACTED]

- [REDACTED]

- [REDACTED]

[REDACTED]

[REDACTED]

- [REDACTED]

[REDACTED]

[REDACTED]

- [REDACTED]
- [REDACTED]

[REDACTED]

[REDACTED]

- [REDACTED]

■ [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

7 RMOG update

■ advised the group that Liothyronine and Adalimumab Guidelines will be discussed at the APMOC meeting on Thursday 15th August 2019.

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

[REDACTED]

[REDACTED]

-
- [REDACTED]
[REDACTED]
[REDACTED]
 - [REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
July 2019

[Redacted]

[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]

BNSSG Drugs and Therapeutics Committee

Date: Wednesday 30th January 2019

Time: 1.00-3.30pm

Location: Boardroom, Lower Ground Floor, South Plaza, Bristol, BS1 3NX

Agenda

		Presenter	Papers
█	[REDACTED]	█	█
█	[REDACTED]	█	█
█	[REDACTED]	█	█
█	[REDACTED]	█	█
█	[REDACTED]	█	█
█	[REDACTED]	█	█
█	[REDACTED]		
	[REDACTED]	█	█
	[REDACTED]		
█	[REDACTED]	█	█
█	[REDACTED]	█	█



		Presenter	Papers
	RMOC		
10	RMOC Update	■	Verbal
11	■	■	Verbal
12	Liothyronine Prescribing in Primary Care	■	Attached
	Medicines Safety / Quality		
■	■	■	■
■	■	■	■
■	■	■	■
■	■	■	■
■	■	■	■
■	■	■	■
■	■	■	■
■	■	■	■
■	■	■	■
■	■	■	■
■	■	■	■
■	■	■	■
■	■	■	■
■	■	■	■



		Presenter	Papers
█	██████████		████
	████████████████████ ████████████████████ ████████████████████		





BNSSG Drug & Therapeutics Committee (D&TC)

Minutes of the meeting held on Wednesday 30th January 2019 at 9am.

Minutes

Present		
[Redacted]	Deputy Director - Medicines Optimisation, CCG (<i>chair</i>)	[Redacted]
[Redacted]	Principal Medicines Optimisation Pharmacist, CCG	[Redacted]
[Redacted]	Senior Pharmacist, Pharmacoeconomics, NBT	[Redacted]
[Redacted]	Consultant, NBT	[Redacted]
[Redacted]	Principal Medicines Optimisation Pharmacist, CCG	[Redacted]
[Redacted]	Senior Medicines Optimisation Pharmacist, CCG	[Redacted]
[Redacted]	Lead Pharmacist – WAHT	[Redacted]
[Redacted]	Pharmacy Manager, Clinical Services, NBT	[Redacted]
[Redacted]	Director of Pharmacy, UHB	[Redacted]
[Redacted]	Principal Medicines Optimisation Pharmacist, CCG	[Redacted]
[Redacted]	NSCP	[Redacted]
[Redacted]	Executive PA, CCG (<i>minute taker</i>)	[Redacted]
Apologies		
[Redacted]	GP Prescribing Lead, CCG	[Redacted]
[Redacted]	GP at Tudor Lodge Surgery, North Somerset	[Redacted]
[Redacted]	CEPN Representative	[Redacted]
[Redacted]	Director of Pharmacy, NBT	[Redacted]
[Redacted]	Lead Pharmacist, NSCP	[Redacted]
[Redacted]	Head of Medicines Management, BCH	[Redacted]

	Item	Action
01	Introductions and Apologies [Redacted]	
02	Declarations of Interest No conflicts of interest were identified.	
[Redacted]	[Redacted]	
[Redacted]	[Redacted]	



	Item	Action
█	<p>█</p> <ul style="list-style-type: none">█████ <p>█</p> <p>█</p>	
█	<p>█</p> <p>█</p> <p>█</p> <p>█</p> <p>█</p>	



	Item	Action
	<p>[Redacted]</p> <p>[Redacted]</p>	
■	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	
■	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted] x to the main guidelines; the committee agreed this suggestion.</p>	
■	<p>[Redacted]</p> <p>[Redacted]</p>	



	Item	Action
	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	
10	Regional Medicines Optimisation Committee (RMOC) Update	



	Item	Action
	<p> ■■ and ■■ provided a verbal update from the RMOC held on Friday 25th January. Key highlights noted were: </p> <ul style="list-style-type: none"> • The RMOC operating model they have in place now is going to seven regions; but it has been put on hold. The impact for the RMOCs has not yet been confirmed. • From April 2020 NICE will approve appraisals of all new medicine. • In the interim RMOCs will review pyridoxine (morning sickness), oral melatonin and inhaled levodopa. • There is a South Productivity and Efficiency Board; which is finance driven. • They are using the BNSSG Botox work as a starting point to see if the RMOCs can give some principles and advice, on which areas should be commissioned or not for use of Botox. There will be a small working group set up • Best value biologics sub group work; agreed the next priority to look at is biosimilar insulin. • Some patients that do biological switching will have to revert to the originated drug. • The national action plan for antimicrobial was published this week. Primary care extra 15% reduction (25% reduction as a whole). • There will be a mechanism from 1st April 2019 for reimbursement to the CCGs for Freestyle Libre®. 	
■■	<div style="background-color: black; height: 100px; width: 100%;"></div> <div style="background-color: black; height: 40px; width: 100%;"></div> <div style="background-color: black; height: 40px; width: 100%;"></div> <div style="background-color: black; height: 40px; width: 100%;"></div> <div style="background-color: black; height: 40px; width: 100%;"></div>	



	Item	Action
	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	
12	<p>Liothyronine Prescribing in Primary Care</p> <p>The House of Lords are debating this and have raised numerous issues of concern; and that there is still a group of patients who cannot metabolise T4, and should be prescribed this.</p> <p>It was agreed that there is some wording that can be reworded to give further clarification; but it would not change in context and the guidance will still apply as it is now. The revised document will be circulated to the committee for comment.</p> <p>RMOC are now aware that they need to include review dates on documents; and that they consider implementing an appeal process.</p>	
█	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	



	Item	Action
	<p>[Redacted]</p> <ul style="list-style-type: none"> - [Redacted] - [Redacted] 	
■	<p>[Redacted]</p> <p>[Redacted]</p>	
■	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	
■	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	



	Item	Action
■	<p>[Redacted]</p> <p>[Redacted]</p>	
■	<p>[Redacted]</p> <p>[Redacted]</p>	
■	<p>[Redacted]</p> <p>[Redacted]</p>	
■	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	
■	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	



	Item	Action
	<p>[Redacted]</p> <p>[Redacted]</p>	
<p>[Redacted]</p>	<p>[Redacted]</p> <p>[Redacted]</p>	
<p>[Redacted]</p>	<p>[Redacted]</p> <p>[Redacted]</p>	
<p>[Redacted]</p>	<p>[Redacted]</p> <p>[Redacted]</p>	
<p>[Redacted]</p>	<p>[Redacted]</p> <p>[Redacted]</p>	

[Redacted]
Executive Personal Assistant
30th January 2019

BNSSG Drugs and Therapeutics Committee (D&TC) - Action Log

Meeting Date & Item No.	Ref.	Action Point	Owner	Timescale	Update/Comments	Status
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
19-Sep-18	33	Self-Care National Guidance & Local Implementation - [Redacted] to share any information with the Group at the next RMOG Meeting in January 2019.	[Redacted]	January		Open
19-Sep-18	36	AOB - RMOG Free of Charge Guidelines/Policy - All Trust Members to let [Redacted] know if any issues re: adopting RMOG policy.	All [Redacted]		Email sent to [Redacted] to asked if adopted and if any issues - asked for response by 18th Jan 19.	Recommend Close
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]

Open Actions

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
21-Nov-2018 Item 8	55	RMOC Update : Liothyronine Guidelines: It was discussed and agreed that these guidelines would be shared with the endocrinologists across all 3 Trusts for their comments. Feedback asap	[REDACTED]	[REDACTED]	[REDACTED]	Open
21-Nov-2018 Item 8	56	RMOC Update : Liothyronine Guidelines: [REDACTED] to search if any on Liothyronine in Primary Care for depression	[REDACTED]	[REDACTED]	Completed - data sent by [REDACTED] - on the agenda.	Recommend Close
21-Nov-2018 Item 8	57	RMOC Update : Liothyronine Guidelines: [REDACTED] to search total number of patients on monotherapy and duel therapy and feed back to acute colleagues.	[REDACTED]	[REDACTED]	Completed - data sent by [REDACTED] - on the agenda.	Recommend Close
21-Nov-2018 Item 8	58	RMOC Update: Acute Trust Leads to share proposals with endocrinologists asap and feedback	Acute Trust Leads	[REDACTED]	Update 2-Jan-2019 - [REDACTED] advised this action can now be closed	Recommend Close
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Open Actions

[REDACTED]	■	[REDACTED]	[REDACTED]			[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]

Closed Actions

		[REDACTED]				
		[REDACTED]				
23-May-18		<p><u>Feedback on RMOG documents</u></p> <ul style="list-style-type: none"> • Lithyronine draft policy • Insulin safety document • Operating model • Primacy/Secondary care prescribing <p>All send feedback to [REDACTED].</p>	All		24-Jul-2018 Update: All feedback received. Closed.	Closed 24-Jul-208
23-May-18		<p><u>RMOG Antibiotic Chart</u></p> <p>To circulate to members for circulation within their organisations.</p>	[REDACTED]		24-Jul-2018 Update: Summary chart circulated to relevant organisations Closed.	Closed 24-Jul-208
23-May-18		<p><u>RMOG Topics</u></p> <p>Form to be completed on SPS website re suggestion Botox use should be reviewed.</p>	[REDACTED]		24-Jul-2018 Update: Botox was discussed but it hasn't been put forward as yet, there will be a big formulary session on Botox locally. Suggestion that it should be a RMOG topic for the future. Close.	Closed 24-Jul-208
		[REDACTED]				
		[REDACTED]				
		[REDACTED]				
		[REDACTED]				
		[REDACTED]				
		[REDACTED]				

Actions Closed from July 2018 onwards

		[REDACTED]				
		[REDACTED]				
		[REDACTED]				
		[REDACTED]				

Closed Actions

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]
19-Sep-18	23	<u>RMOC Update.</u> ■ will circulate agenda for latest meeting electronically when available. All to give feedback to ■ to take forward to next meeting.	■/All	21-Nov-18	On agenda for discussion at this meeting 21 st November 2019	Recommend Close
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
19-Sep-18	28	■ to liaise with John [REDACTED]	■	21-Nov-18	■ provided an update and stated that there was an RMOC Homely Remedies Guidelines that came out, so discussion was to look at this in more detail. It was agreed to close this action, but to open a new action to review both Guidelines and work out if we want to change what we have	Recommend Close
19-Sep-18	29	JC to send RS Homely Remedies Guidelines	JC	ASAP	This has been actioned	Recommend Close
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]

Open Actions

[REDACTED]	■	[REDACTED]	[REDACTED]			[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]			[REDACTED]

Closed Actions

[REDACTED]		[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]		[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
		[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	■	[REDACTED]	■
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	■
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	■
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	■
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	■
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	■
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	■
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	■
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	■
19-Sep-18	23	<u>RMOC Update</u> ■ will circulate agenda for latest meeting electronically when available. All to give feedback to ■ to take forward to next meeting.	■ /All	21-Nov-18	On agenda for discussion at this meeting 21 st November 2019	Closed
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	■
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	■
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	■
19-Sep-18	28	Homely remedies Guidelines - The Author [REDACTED] to liaise with [REDACTED]	JT	21-Nov-18	■ provided an update and stated that there was an RMOC Homely Remedies Guidelines that came out, so discussion was to look at this in more detail. It was agreed to close this action, but to open a new action to review both Guidelines and work out if we want to change what we have	Closed
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	■
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	■
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	■
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	■
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	■
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	■
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	■

BNSSG Area Prescribing Medicines Optimisation Committee (APMOC)

Minutes of the meeting held on Wednesday 10th April 2019

Minutes

Present		
██████████	Deputy Director (Medicines Optimisation) BNSSG CCG (<i>chair</i>)	■
██████████	Principal Medicines Optimisation Pharmacist, BNSSG CCG	■
██████████	Interface Pharmacist, BNSSG CCG	■
██████████	Principal Medicines Optimisation Pharmacist, BNSSG CCG	■
██████████	Lead Pharmacist – WAHT	■
██████████	GP, Clinical Chair CCG	■
██████████	Head of Medicines Management, NSCP	■
██████████	Director of Pharmacy, UHB	■
██████████	Team Administrator, BNSSG CCG (<i>minute taker</i>)	■
Apologies		
██████████	Team Administrator, BNSSG CCG	■
██████████	GP, Prescribing Lead, CCG	■
██████████	Pharmacy Manager, Clinical Services, NBT	■
██████████	Strategic Lead for Pharmaceutical Services, Sirona Health	■
██████████	Principal Medicines Optimisation Pharmacist, BNSSG CCG	■
██████████	Consultant, NBT	■
██████████	Senior Pharmacist, Pharmacoeconomics, NBT	■
██████████	Principal Medicines Optimisation Pharmacist, BNSSG CCG	■
██████████	Non-Medical Prescriber Representative	■
██████████	Director of Pharmacy, NBT	■
██████████	Head of Medicines Management, BCH	■
██████████	Deputy Chief Pharmacist, AWP	■

	Item	Action
01	<p>Introductions and Apologies</p> <p>██ It was discussed that the meeting was not quorate as there was no consultant representation. Any decisions/recommendations agreed in principle today, will have to be ratified virtually or carried over to the next meeting.</p>	

	Item	Action
02	Declarations of Interest No conflicts of interest were identified.	
■	[Redacted text]	
■	[Redacted text]	
■	[Redacted text]	
■	[Redacted text]	

	Item	Action
	<p>[Redacted text block]</p>	<p>[Redacted text block]</p>
07	<p>Guidelines & Pathways</p> <p>[Redacted text block]</p>	
█	<p>[Redacted text block]</p>	



	Item	Action
	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]



	Item	Action
	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>
07f	<p>Homely Remedies Guidelines</p> <p>HW discussed the Homely Remedies guidelines. Bristol and North Somerset's polices have been merged for BNSSG and APMOC have provided some recommendations, which have been included. In RMOC's guidelines, nurses in care homes can provide homely remedies for individual residents in place of a GP. This guidance excludes nurses from making this decision, as there is uncertainty about the competence of all care home nurses making this decision safely. It was also felt that there should be a separation between the task of authorising the use of homely remedies and the administration. The original guidance stated every homely remedy should be authorised by a GP. This has been changed on the new guidelines to be authorised by a GP, Pharmacist or non-medical prescriber. This will help in reducing GPs workload. There was a debate to whether you could have a home remedy plan for the whole home, or if it should be on an individual basis. RMOC agreed that it would need to be individualised for each patient.</p> <p>The group agree with the new guidelines, to be circulated to the whole group for ratification.</p>	
[REDACTED]	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	



	Item	Action
	An RMOC update has been circulated to everyone in the group RMOC have not met since. The Liothyronine final document will be circulated to the group shortly.	■
■	<p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED][REDACTED][REDACTED] <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	
■	<p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED][REDACTED][REDACTED] <p>[REDACTED]</p>	
■	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	



	Item	Action
	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	
■	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	
■	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	■
■	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	■
■	<p>[REDACTED]</p> <p>[REDACTED]</p>	■

[REDACTED]
 Wednesday 10th April 2019

BNSSG Area Prescribing Medicines Optimisation Committee (APMOC - formerly known as DTC) - Action Log



Meeting Date & Item No.	Ref.	Action Point	Owner	Timescale	Update/Comments	Status
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
Actions from 21st November 2018 Meeting						
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
Actions from 30th January 2019 Meeting						
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]



Closed Actions

[REDACTED]		[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]		[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
		[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	■	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]
19-Sep-18	23	<u>RMOC Update</u> DC will circulate agenda for latest meeting electronically when available. All to give feedback to [REDACTED] to take forward to next meeting.	DC/AI	21-Nov-18	On agenda for discussion at this meeting 21 st November 2019	Closed
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
19-Sep-18	28	Homely remedies Guidelines - The Author [REDACTED] to liaise with [REDACTED]	JT	21-Nov-18	[REDACTED] provided an update and stated that there was an RMOC Homely Remedies Guidelines that came out, so discussion was to look at this in more detail. It was agreed to close this action, but to open a new action to review both Guidelines and work out if we want to change what we have	Closed
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]



BNSSG Area Prescribing Medicines Optimisation Committee (APMOC)

Minutes of the meeting held on Thursday 20th June 2019

Minutes

Present		
[Redacted]	Deputy Director (Medicines Optimisation) BNSSG CCG <i>(chair)</i>	[Redacted]
[Redacted]	Principal Medicines Optimisation Pharmacist, BNSSG CCG	[Redacted]
[Redacted]	Principal Medicines Optimisation Pharmacist, BNSSG CCG	[Redacted]
[Redacted]	Non-Medical Prescriber Representative	[Redacted]
[Redacted]	Director of Pharmacy, NBT	[Redacted]
[Redacted]	Senior Medicines Optimisation Pharmacist	[Redacted]
[Redacted]	Head of Medicines Management, NSCP	[Redacted]
[Redacted]	Health watch North Somerset Volunteer	[Redacted]
[Redacted]	GP, Prescribing Lead, CCG	[Redacted]
[Redacted]	Principal Medicines Optimisation Pharmacist, BNSSG CCG	[Redacted]
[Redacted]	Pharmacy Manager, Clinical Services, NBT	[Redacted]
[Redacted]	Team Administrator & Minute Taker, BNSSG CCG	[Redacted]
Apologies		
[Redacted]	Lead Pharmacist – WAHT	[Redacted]
[Redacted]	Consultant, Public Health	[Redacted]
[Redacted]	Director of Pharmacy, UHB	[Redacted]
[Redacted]	Interim Head of Nursing, BNSSG CCG	[Redacted]
[Redacted]	GP, Clinical Chair CCG	[Redacted]
[Redacted]	Strategic Lead for Pharmaceutical Services, Sirona Health	[Redacted]
[Redacted]	Consultant, NBT	[Redacted]
[Redacted]	Senior Pharmacist, Pharmacoeconomics, NBT	[Redacted]
[Redacted]	Principal Medicines Optimisation Pharmacist, BNSSG CCG	[Redacted]
[Redacted]	Head of Medicines Management, BCH	[Redacted]
[Redacted]	Deputy Chief Pharmacist, AWP	[Redacted]









	Item	Action
01	<p>Introductions and Apologies</p> <p>[REDACTED]</p> <p>It was discussed that the meeting was not quorate as there was no consultant representation. Any decisions/recommendations agreed in principle today, would have to be ratified virtually and circulated via email for agreement and formal sign off.</p>	
02	<p>Declarations of Interest</p> <p>No conflicts of interest were identified.</p>	
█	<p>[REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] <p>[REDACTED]</p>	
█	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	█
█	<p>[REDACTED]</p> <p>[REDACTED]</p>	



	Item	Action
	[Redacted]	[Redacted]
6 [Redacted]	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	[Redacted]



	Item	Action
	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

	Item	Action
	  	
	 	



	Item	Action
	[Redacted]	[Redacted]
■	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	■
■	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	■
7	<p>RMOC – Update</p> <p>The RMOC notes were included in the papers for information.</p> <p>Liothyronine – ■ advised that Weston consultants have written out to their patients to advise they will no longer be prescribing this. Still awaiting final guidance and will discuss at the next meeting.</p>	
■	<p>[Redacted]</p> <p>[Redacted]</p>	

	Item	Action
	<p>[Redacted]</p> <ul style="list-style-type: none"> ■ [Redacted] ■ [Redacted] ■ [Redacted] 	
<ul style="list-style-type: none"> ■ [Redacted] 	<p>[Redacted]</p> <ul style="list-style-type: none"> ■ [Redacted] 	
Discussion		
<ul style="list-style-type: none"> ■ [Redacted] 	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	



	Item	Action
	[Redacted]	
	[Redacted]	
	[Redacted]	
	[Redacted]	
	[Redacted]	
	[Redacted]	
	[Redacted]	



	Item	Action
	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	<p>[Redacted]</p>
<ul style="list-style-type: none"> ■ [Redacted] 	<ul style="list-style-type: none"> ■ [Redacted] ■ [Redacted] ■ [Redacted] ■ [Redacted] ■ [Redacted] 	<ul style="list-style-type: none"> ■ [Redacted] ■ [Redacted]
<ul style="list-style-type: none"> ■ [Redacted] 	<p>[Redacted]</p>	
<ul style="list-style-type: none"> ■ [Redacted] 	<p>[Redacted]</p>	



	[REDACTED]	
	[REDACTED]	
	[REDACTED]	[REDACTED]
	[REDACTED]	
[REDACTED]	[REDACTED]	[REDACTED]
	[REDACTED]	[REDACTED]
	[REDACTED]	
	[REDACTED]	
	[REDACTED]	
	[REDACTED]	
	[REDACTED]	
	[REDACTED]	
	[REDACTED]	
	[REDACTED]	
[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED] - June 2019

BNSSG Area Prescribing Medicines Optimisation Committee (APMOC)

Minutes of the meeting held on Thursday 15th August 2019

Time: 9:00am – 11:30am

Location: Southmead Hospital (Pharmacy Seminar Room)

Minutes

Present		
██████████	Deputy Director (Medicines Optimisation) BNSSG CCG <i>(chair)</i>	■
██████████	Principal Medicines Optimisation Pharmacist, BNSSG CCG	■
██████████	Principal Medicines Optimisation Pharmacist, BNSSG CCG	■
██████████	Non-Medical Prescriber Representative	■
██████████	Director of Pharmacy, NBT	■
██████████	Lead Pharmacist – WAHT	■
██████████	Head of Medicines Management, NSCP	■
██████████	Lay Member Volunteer - Health Watch North Somerset	■
██████████	Senior Pharmacist, Pharmacoeconomics, NBT	■
██████████	Director of Pharmacy, UHB	■
██████████	Pharmacy Manager, Clinical Services, NBT	■
██████████	Principal Medicines Optimisation Pharmacist, BNSSG CCG	■
██████████	Team Administrator & Minute Taker, BNSSG CCG	■
Apologies		
██████████	GP, Prescribing Lead, CCG	■
██████████	Consultant, Public Health	■
██████████ ██████████	Interim Head of Nursing, BNSSG CCG	■
██████████	GP, Clinical Chair CCG	■
██████████	Strategic Lead for Pharmaceutical Services, Sirona Health	■
██████████	Consultant, NBT	■
██████████	Head of Medicines Management, BCH	■
██████████	Deputy Chief Pharmacist, AWP	■

	Item	Action
1	<p>Welcome, Introductions and Apologies</p> <p>[Redacted] [Redacted]</p> <p>[Redacted] It was discussed that the meeting was not quorate as there was no consultant/GP representation. Any decisions/recommendations agreed in principle today, would have to be ratified virtually and circulated via email for agreement and formal sign off.</p>	
2	<p>Declarations of Interest</p> <p>No conflicts of interest were identified.</p>	
■	<p>[Redacted] ■ [Redacted]</p> <p>[Redacted] ■ [Redacted]</p> <p>[Redacted]</p>	
■	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	
■	<p>[Redacted]</p> <p>[Redacted]</p>	
<ul style="list-style-type: none"> ■ ■ 	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	<p>[Redacted]</p> <p>[Redacted]</p>



	Item	Action
	<p>[Redacted text block]</p>	<p>[Redacted action]</p>
■	<p>[Redacted text block]</p>	<p>[Redacted action]</p>



	Item	Action
	<p>[Redacted]</p>	
■	<p>[Redacted]</p>	■ ■
■	<p>[Redacted]</p>	



	Item	Action
	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>
7	<p>RMOC – Update</p> <p>The RMOC notes were included in the papers for information.</p> <p>➤ RMOC – Liothyronine</p> <p>The “Guidance - Prescribing of Liothyronine” document was discussed, [REDACTED] mentioned a discussion was required and agree what we do locally. [REDACTED] reported this from a Formulary point of view, this was currently on Formulary as red; and feels in her opinion, and this should remain red. [REDACTED] suggested the potential of a shared care with the GPs, following the RMOC guidance. It was reported that UHB advised no consultants want to prescribe Liothyronine. [REDACTED] reported mixed reviews from NBT, stating some consultants do want to prescribe and others do not want to prescribe it. [REDACTED] reported that she felt some GPs would not feel comfortable in picking up the shared care and expressed her concerns of the inconsistency of reviews.</p> <p>[REDACTED] spoke regarding traffic light status that if a consultant has made a judgement for a patient to be on Liothyronine, it was going to be difficult to challenge it not being amber. It was discussed this would need further follow up to finally agree this and to follow the principles. It was agreed to get the endocrinologists from all 3 Trusts to meet with pharmacist leads and discuss pathways and how locally will take up the RMOC guidance. [REDACTED] reported that the Trust is aware of complaints received at Weston General Hospital with Liothyronine.</p> <p>Action – [REDACTED] to provide the name of their respective endocrinologist, together with contact details, to enable [REDACTED] to facilitate a meeting for them to discuss this through and agree a collaborative and consistent approach.</p> <p>Action - [REDACTED] to set up a meeting with the endocrinologists from the 3 Trusts, to discuss pathways. Meeting to include [REDACTED] from the CCG. It was suggested to invite [REDACTED] and possibly [REDACTED]. This meeting to be set up before the next APMOC meeting in October 2019.</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>
[REDACTED]	<p>[REDACTED]</p> <p>[REDACTED]</p>	



	Item	Action
	<p>[Redacted text block]</p>	<p>[Redacted action]</p>
9	<p>[Redacted text block]</p>	<p>[Redacted action]</p>

	Item	Action
	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	<p>[Redacted]</p>
10	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	



	Item	Action
	<p>[REDACTED]</p> <p>[REDACTED]</p>	
11	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	
12	<p>[REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] 	
13	<p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] 	

	[Redacted]	[Redacted]
14	<p>[Redacted]</p> <ul style="list-style-type: none">■ [Redacted]■ [Redacted]■ [Redacted]	
15	<p>Minutes from Other Meetings</p> <p>The minutes from the meetings below are for information.</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>RMOC minutes and papers to be added to the next APMOC meeting</p>	[Redacted]
16	<p>[Redacted]</p> <p>[Redacted] ■ [Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	

	[REDACTED]	
	[REDACTED]	
	[REDACTED]	
	[REDACTED]	
	[REDACTED]	

[REDACTED] - August 2019



BNSSG Area Prescribing Medicines Optimisation Committee (APMOC) - Action Log



Meeting Date & Item No.	Ref.	Action Point	Owner	Timescale	Update/Comments	Status
Actions from 21st November 2018 Meeting						
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
Actions from 10th April 2019 Meeting						
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	Open
Actions from 20th June 2019 Meeting						
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
Actions from 15th Aug 2019 Meeting						
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]

Open Actions

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]			[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]			[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]			[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]			[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]			[REDACTED]
15/08/2019 Item 7 - Guidance - Prescribing of Liothyronine	146	<p>Guidance - Prescribing of Liothyronine and Pathways to set up a meeting with the endocrinologists from the 3 Trusts, to agree pathways. Meeting to include [REDACTED] from the CCG. It was suggested to invite [REDACTED] and [REDACTED]. This meeting to be set up before the next APMOC meeting in October 2019</p>	[REDACTED]		<p>Update 20Oct2019 - [REDACTED] has emailed the 3 x endocrinologists to try to arrange a meeting re: Prescribing of Liothyronine and Pathways</p>	Open
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]			[REDACTED]

Closed Actions

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
10/04/2019 Item 8	97	RMOC update [REDACTED] to circulate to the group the Liothyronine final documents when available.	[REDACTED]	[REDACTED]	Update 20 June 2019 - [REDACTED] advised this was still not available, but she would share with the group when she is able to. Update 15 Aug 2019 - on Agenda to discuss at this meeting.	Recommend Close
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Closed Actions

[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-

[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-

[REDACTED]	-	[REDACTED]	+		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	+		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-

[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	+		[REDACTED]	-

[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
------------	---	------------	---	--	------------	---

Closed Actions

<p>15/08/2019 Item 7 - Guidance - Prescribing of Liothyronine</p>	<p>145</p>	<p>Guidance - Prescribing of Liothyronine and Pathways [redacted] to provide the name of their respective endocrinologist, together with contact details, to enable to facilitate a meeting for them to discuss this through</p>	<p>[redacted]</p>		<p>Update 28Aug2019. [redacted] has sent a chase reminder email, to ask for respective endocrinologists from the 3 Trusts, to allow a meeting to be facilitated.</p>	<p>Recommend to Close</p>
<p>[redacted]</p>	<p>[redacted]</p>	<p>[redacted]</p>	<p>[redacted]</p>		<p>[redacted]</p>	<p>[redacted]</p>
<p>[redacted]</p>	<p>[redacted]</p>	<p>[redacted]</p>	<p>[redacted]</p>		<p>[redacted]</p>	<p>[redacted]</p>
<p>[redacted]</p>	<p>[redacted]</p>	<p>[redacted]</p>	<p>[redacted]</p>		<p>[redacted]</p>	<p>[redacted]</p>
<p>[redacted]</p>	<p>[redacted]</p>	<p>[redacted]</p>	<p>[redacted]</p>		<p>[redacted]</p>	<p>[redacted]</p>

BNSSG Area Prescribing Medicines Optimisation Committee (APMOC)

Minutes of the meeting held on Thursday 5th December 2019

Time: 09:00am – 11:30am

Location: Southmead Hospital – Pharmacy Room

Minutes

Present		
██████████	Deputy Director (Medicines Optimisation) BNSSG CCG (<i>chair</i>)	█
██████████	Team Administrator, BNSSG CCG (<i>minutes</i>)	█
██████████	Principal Medicines Optimisation Pharmacist, BNSSG CCG	█
██████████	Interface Pharmacist, BNSSG CCG	█
██████████	Director of Pharmacy, NBT	█
██████████	GP, Prescribing Lead, CCG	█
██████████	Head of Medicines Management, NSCP	█
██████████	Director of Pharmacy, UHB (from 10:30)	█
██████████	Team Administrator, BNSSG CCG	█
██████████	Senior Pharmacist, Pharmacoeconomics, NBT	█
██████████	Lead Pharmacist – WAHT	█
██████████	Principal Medicines Optimisation Pharmacist, BNSSG CCG	█
██████████	Interface Pharmacist, BNSSG CCG	█
██████████	Medicines Optimisation Pharmacist, BNSSG CCG	█
██████████	Pharmacy Manager Principal Pharmacist, UHB	█
██████████	Clinical Practice Pharmacist	█
██████████	Medicines Information Pharmacists, UHB	█
Apologies		
██████████	Head of Medicines Management, BCH	█
██████████	Principal Medicines Optimisation Pharmacist, BNSSG CCG	█
██████████	Principal Medicines Optimisation Pharmacist, BNSSG CCG	█
██████████	Consultant, Public Health	█
██████████	Lay Member Volunteer - Health Watch North Somerset	█
██████████	GP, Clinical Chair CCG	█
██████████	Strategic Lead for Pharmaceutical Services, Sirona Health	█
██████████	Consultant, NBT	█
██████████	Deputy Chief Pharmacist, AWP	█

	Item	Action
1	<p>Welcome, Introductions and Apologies</p> <p>DC opened the meeting. ██████████ It was discussed that the meeting was not quorate as there was no consultant representation. Any decisions/recommendations agreed in principle today, would have to be ratified virtually and circulated via email for agreement and formal sign off.</p>	

	Item	Action
	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <p>[REDACTED]</p> <p>Action 160 – RMOC update, Ophthalmologists – It was confirmed that Ophthalmologists are unable to complete the necessary retinal or retinal screening. The group agreed this action can be closed.</p> <p>Action 161 & 162 – RMOC update, Hydroxychloroquine – This is on the STP Medicines Optimisation Quality & Safety agenda for Thursday 19th December. Action can be closed.</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED]	<p>[REDACTED]</p>

Decision



	Item	Action
■	[Redacted]	
■	[Redacted]	
■	[Redacted]	
■	[Redacted]	



	Item	Action
	[REDACTED]	
■	[REDACTED]	
	[REDACTED]	
■	[REDACTED]	
	[REDACTED]	
■	[REDACTED]	
	[REDACTED]	
■	[REDACTED]	



	Item	Action
	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>
Strategic		
6	<p>RMOC – Update</p> <p>Minutes from September Meeting The September RMOC minutes were circulated to the group. No comments/feedback was raised regarding these minutes. The RMOC meeting will take place on Friday 24th January 2020. [REDACTED] will circulate the Blueteq principal's document regarding set templates to the group to review.</p> <p>Action: [REDACTED] to circulate Blueteq principal's document to the group</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>Low Value Medicine Programme [REDACTED] updated on the low value medicines prescribing programme from acute and primary care settings. There is a possibility this would be part of the system assurance framework.</p>	<p>[REDACTED]</p>
■	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>
Discussion		
■	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>



	Item	Action
	[Redacted]	
■	[Redacted]	



	Item	Action
■	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	
[REDACTED]		
■	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	■
■	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	■
[REDACTED]		
■	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	
Standing Items		
14	<p>New NICE Guidance</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] 	

	Item	Action
	<ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] Thyroid disease: assessment and management states Liothyronine for primary hypothyroidism should not routinely be prescribed. [REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	
■	<p>[REDACTED]</p> <p>[REDACTED]</p>	
	<p>[REDACTED]</p>	
	<p>[REDACTED]</p>	
	<p>[REDACTED]</p>	
	<p>[REDACTED]</p>	
■	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	
■	<p>[REDACTED]</p> <p>[REDACTED]</p>	

[REDACTED] – December 2019



BNSSG Drugs and Therapeutics Committee (D&TC) - CLOSED ACTIONS

Meeting Date & Item No.	Ref.	Action Point	Owner	Timescale	Update/Comments	Status
		[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
		[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
		[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
		[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
		[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
		[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
		[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
		[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
		[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
		[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
		[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
		[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
		[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
		[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
		[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
	04	RMOC Update - Prescribing of Liothyronine Guidance All members of the committee to feedback to [REDACTED] any comments on the Liothyronine guidance by the 26th July 2018.	All	19-Sep-08	Comments snt to RMOC	Close
						Close
	03	RMOC Update - Best Value Biologics Adalimumab – work being done nationally to plan to release savings as quickly as possible. All members of the committee to share the toolkit when it is available with all relevant clinicians throughout the trusts.	All	19-Sep-08	All to update	Close
		[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
		[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
23-May-18		Feedback on RMOC documents • Liothyronine draft policy • Insulin safety document • Operating model • Primary/Secondary care prescribing All send feedback to [REDACTED].	All		24-Jul-2018 Update: All feedback received. Closed.	Close
23-May-18		RMOC Antibiotic Chart To circulate to members for circulation within their organisations.	[REDACTED]		24-Jul-2018 Update: Summary chart circulated to relevant organisations Closed.	Close
23-May-18		RMOC Topics Form to be completed on SPS website re suggestion Botox use should be reviewed.	[REDACTED]		24-Jul-2018 Update: Botox was discussed but it hasn't been put forward as yet, there will be a big formulary session on Botox locally. Suggestion that it should be a RMOC topic for the future. Close.	Close
		[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
		[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
		[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Closed Actions

19-Sep-18	23	<p><u>RMOC Update</u></p> <p>will circulate agenda for latest meeting electronically when available. All to give feedback to to take forward to next meeting.</p>	/All	21-Nov-18	On agenda for discussion at this meeting 21 st November 2019	Close
19-Sep-18	28	<p>Homely remedies Guidelines - The Author to liaise with</p>		21-Nov-18	<p>in RMOC</p> <p>Homely Remedies Guidelines that came out, so discussion was to look at this in more detail. It was agreed to close this action, but to open a new action to review both Guidelines and work out if we want to change what we have</p>	Close
19-Sep-18	33	<p><u>Self-Care National Guidance & Local Implementation</u> - to share any information with the Group at the next RMOC Meeting in January 2019.</p>		January		Close
19-Sep-18	36	<p><u>AOB - RMOC Free of Charge Guidelines/Policy</u> - All Trust Members to let know if any issues re: adopting RMOC policy.</p>	All		<p>Email sent to to asked if adopted and if any issues - asked for response by 18th Jan 19.</p>	Close

Closed Actions

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
10/04/2019 Item 8	97	RMOC update [REDACTED] to circulate to the group the Liothyronine final documents when available.	[REDACTED]	[REDACTED]	Update 20 June 2019 - [REDACTED] advised this was still not available, but she would share with the group when she is able to. Update 15 Aug 2019 - on Agenda to discuss at this meeting.	Close
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Closed Actions

[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	-
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	-
[REDACTED]	-	[REDACTED]	+		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	+		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-
[REDACTED]	-	[REDACTED]	-		[REDACTED]	-

Closed Actions

[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
15/08/2019 Item 7 - Guidance - Prescribing of Liothyronine	145	Guidance - Prescribing of Liothyronine and Pathways [REDACTED] to provide the name of their respective endocrinologist, together with contact details, to enable to facilitate a meeting for them to discuss this through [REDACTED]	[REDACTED]		Update 28Aug2019. [REDACTED] has sent a chase reminder email, to ask for respective endocrinologists from the 3 Trusts, to allow a meeting to be facilitated.	Recommend to Close
[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]



BNSSG Area Prescribing Medicines Optimisation Committee (APMOC)

Minutes of the meeting held on Thursday 6th February 2020

Time: 09:30am – 11:30am

Location: South Plaza- Executive Board room

Minutes


Present		
		Deputy Director (Medicines Optimisation) BNSSG CCG (<i>chair</i>)
		Head of Medicines Management, BCH
		Principal Medicines Optimisation Pharmacist, BNSSG CCG
		Principal Medicines Optimisation Pharmacist, BNSSG CCG
		Lay Member Volunteer - Health Watch North Somerset
		Clinical Lead, Sirona (shadowing [redacted])
		Principal Medicines Optimisation Pharmacist, BNSSG CCG
		Medication Safety Officer , Clinical Governance Pharmacist UHB
		GP Clinical lead, CCG
		Team Administrator, BNSSG CCG (Minutes)
		Associate Director of Pharmacy (Business Planning), NBT
		GP Partner, Streamside Surgery and Avon LMC
		Interface Pharmacist, BNSSG CCG
		Medicines Optimisation Pharmacist, BNSSG CCG (Part)
		Clinical Practice Pharmacist
		Senior Medicines Optimisation Pharmacist, BNSSG CCG (Part)
Apologies		
		Principal Medicines Optimisation Pharmacist, BNSSG CCG
		Director of Pharmacy, NBT
		GP, Prescribing Lead, CCG
		Pharmacy Manager Principal Pharmacist, UHB
		Consultant, Public Health
		Director of Pharmacy, UHB
		Lead Pharmacist, North Somerset Community Partnership
		Lead Pharmacist- WAHT
		Chief Officer, Avon LPC
		Head of Medicines Management, NSCP
		Strategic Lead for Pharmaceutical Services, Sirona Health
		Neurology Consultant, NBT
		Deputy Chief Pharmacist, AWP

	Item	Action
1	Welcome, Introductions and Apologies	



	Item	Action
	[REDACTED] It was discussed that the meeting was not quorate as there was no consultant representation. Any decisions/recommendations agreed in principle today, would have to be ratified virtually and circulated via email for agreement and formal sign off.	
2	Declarations of Interest No conflicts of interest were identified.	
	[REDACTED]	
	[REDACTED]	



	Item	Action
█	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	
█	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p> [Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>█ [Redacted] █</p>	

	Item	Action
■	<p>[Redacted]</p> <p>[Redacted]</p> <ul style="list-style-type: none"> ■ [Redacted] ■ [Redacted] ■ [Redacted] <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <ul style="list-style-type: none"> ■ [Redacted] 	■



	Item	Action
■	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <ul style="list-style-type: none">[Redacted][Redacted][Redacted][Redacted][Redacted][Redacted][Redacted][Redacted][Redacted][Redacted] <p>[Redacted]</p>	





	Item	Action
	<ul style="list-style-type: none"> <li data-bbox="213 271 1273 342">■ [Redacted] <li data-bbox="213 371 1262 412">■ [Redacted] <li data-bbox="213 450 1233 555">■ [Redacted] <li data-bbox="213 589 1281 663">■ [Redacted] 	■
■	<p data-bbox="165 696 1281 770">[Redacted]</p> <p data-bbox="165 801 1281 1122">[Redacted]</p> <p data-bbox="165 1153 1281 1406">[Redacted]</p>	
■	<p data-bbox="165 1473 839 1514">[Redacted]</p> <p data-bbox="165 1543 1281 1756">[Redacted]</p> <p data-bbox="165 1787 1206 1827">[Redacted]</p>	
■	<p data-bbox="165 1895 727 1935">[Redacted]</p> <p data-bbox="165 1966 1281 2033">[Redacted]</p>	



	Item	Action
	<p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] 	<p>■</p>
<p>■</p>	<p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] <p>[REDACTED]</p>	

	Item	Action
	<ul style="list-style-type: none"> █ [Redacted] █ [Redacted] █ [Redacted] █ [Redacted] <p>[Redacted]</p> <ul style="list-style-type: none"> █ [Redacted] 	<ul style="list-style-type: none"> █

Strategic

6	<p>RMOC – Update</p> <p>Notes from Friday 24th January 2020 meeting-</p> <p>█ highlighted the following items from the meeting. There have been some published guidelines that have gone on the SPS website.</p> <p> Item-5.-South-RMOC -published-guidance- (</p> <ul style="list-style-type: none"> • FOC • Prior approval BlueTeq principles – the BlueTeq contract is up in 12 months, so written fairly generically to allow principles to be used for any tool in the future • Sequential use Biologics - one issue, in context when writing advice was meant for inflammatory conditions, however if apply wording to cancer, it does not quite fit, so asked for exclusion therefore wording will be updated appropriately. These will be picked up through HCD group if necessary. <p> Item-6.-Hydroxychloroquine-RMOC-Briefir</p> <hr/> <p>Item 6 – Hydroxychloroquine Briefing attached with summary of issues and with proposed screening. █ requested that the Hydroxychloroquine is discussed further at Medicines Quality and Safety Group. The</p>	
---	---	--



	Item	Action
	<p>remaining guidelines are mostly work in progress- AMR Programme, Best Value Biologics. [redacted] asked about Biosimilar insulin's – CSU presented toolkit, where there was positive feedback.</p> <ul style="list-style-type: none"> • Action: 187 Medicines, Quality and Safety group to pick up Hydroxychloroquine, which can then be brought back to APMOC to update and to see what needs to be put in place. • Action: 188 [redacted] to have a look at Insulin toolkit and feedback. 	<p>[redacted]</p> <p>[redacted]</p>
<p>[redacted]</p>	<p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p>	<p>[redacted]</p>
<p>[redacted]</p>	<p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p>	<p>[redacted]</p>

	Item	Action
	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>
	<p>[REDACTED]</p>	<p>[REDACTED]</p>
	<p>[REDACTED]</p>	
	<p>[REDACTED]</p>	
	<p>[REDACTED]</p>	
	<p>[REDACTED]</p>	
	<p>[REDACTED]</p>	



	Item	Action
	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	<p>[Redacted]</p>
<p>[Redacted]</p>	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	



	Item	Action
	<p>[Redacted]</p> <p>[Redacted]</p>	
■	<p>[Redacted]</p> <p>[Redacted]</p>	
	<p>[Redacted]</p>	
■	<p>[Redacted]</p> <p>[Redacted]</p>	
■	<p>[Redacted]</p> <p>[Redacted]</p>	
	<p>[Redacted]</p>	
■	<p>[Redacted]</p> <p>[Redacted]</p>	

	Item	Action
Standing Items		
■	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	■
■	<p>[REDACTED]</p> <p>[REDACTED]</p>	
	[REDACTED]	
	[REDACTED]	
	[REDACTED]	
	[REDACTED]	
■	<p>[REDACTED]</p> <p>[REDACTED]</p>	
■	[REDACTED]	

[REDACTED]
January 2020



BNSSG Area Prescribing Medicines Optimisation Committee (APMOC) - Action Log

Meeting Date & Item No.	Ref.	Action Point	Owner	Timescale	Update/Comments	Status
Actions from 20th June 2019 Meeting						
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
Actions from 5th December 2019 Meeting						
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
Actions from 6th February 2020 meeting						
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]

S:\Medical Directorate CE\Shared Area\

Closed Actions

[REDACTED]		[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]		[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
		[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	■	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	■	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]
19-Sep-18	23	<u>RMOC Update</u> [REDACTED] will circulate agenda for latest meeting electronically when available. All to give feedback to [REDACTED] to take forward to next meeting.	[REDACTED] /All	21-Nov-18	On agenda for discussion at this meeting 21 st November 2019	Close
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
19-Sep-18	28	Homely remedies Guidelines - The Author [REDACTED] to liaise with [REDACTED]	■	21-Nov-18	Homely Remedies Guidelines that came out, so discussion was to look at this in more detail. It was agreed to close this action, but to open a new action to review both Guidelines and work out if we want to change what we have	Close
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Closed Actions

		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
19-Sep-18	33	Self-Care National Guidance & Local Implementation - [Redacted] to share any information with the Group at the next RMOC Meeting in January 2019.		January		Close
19-Sep-18	36	AOB - RMOC Free of Charge Guidelines/Policy - All Trust Members to let [Redacted] know if any issues re: adopting RMOC policy.	All [Redacted]		Email sent to [Redacted] to asked if adopted and if any issues - asked for response by 18th Jan 19.	Close
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
21-Nov-2018 Item 8	55	RMOC Update : Liothyronine Guidelines: It was discussed and agreed that these guidelines would be shared with the endocrinologists across all 3 Trusts for their comments. Feedback asap				Close
21-Nov-2018 Item 8	56	RMOC Update : Liothyronine Guidelines: [Redacted] to search if any on Liothyronine in Primary Care for depression			Completed - data sent by [Redacted] - on the agenda.	Close
21-Nov-2018 Item 8	57	RMOC Update : Liothyronine Guidelines: [Redacted] to search total number of patients on monotherapy and duel therapy and feed back to acute colleagues.			Completed - data sent by [Redacted] - on the agenda.	Close
21-Nov-2018 Item 8	58	RMOC Update: Acute Trust Leads to share proposals with endocrinologists asap and feedback	Acute Trust Leads		Update 2-Jan-2019 - [Redacted] advised this action can now be closed	Close
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	
		[Redacted]			[Redacted]	

Closed Actions

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
10/04/2019 Item 8	97	RMOC update [REDACTED] to circulate to the group the Liothyronine final documents when available.	[REDACTED]	[REDACTED]	Update 20June2019 - [REDACTED] advised this was still not available, but she would share with the group when she is able to. Update 15Aug2019 - on Agenda to discuss at this meeting.	Close
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Closed Actions

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
15/08/2019 Item 7 - Guidance - Prescribing of Liothyronine	146	Guidance - Prescribing of Liothyronine and Pathways Admin to set up a meeting with the endocrinologists from the 3 Trusts, to agree pathways. Meeting to include [REDACTED] from the CCG. It was suggested to invite [REDACTED]. This meeting to be set up before the next APMOC meeting in December 2019	Admin		Update 20Oct2019 - Admin has emailed the 3 x endocrinologists to try to arrange a meeting re: Prescribing of Liothyronine and Pathways Invite [REDACTED] - starting criteria and stopping criteria. Update November - Guidance of Prescribing of
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
17/10/2019 Item 6	160	RMOC Update [REDACTED] to check with ophthalmologists what the process of retinal or diabetic retinal screening is	[REDACTED]		Update December- It was confirmed that Ophthalmologists are unable to complete retinal or diabetic retinal screening. The group agreed this action can be closed.
17/10/2019 Item 6	161	RMOC Update for [REDACTED] (CCG) to provide Hydroxychloroquine data received from practices, to present at the next STP Medicines Quality and Safety meeting, for assurance this is being done.	[REDACTED]		Update December - This is on the Quality & Safety agenda f
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
05/12/2019 Item 6	175	RMOC Update [REDACTED] will circulate the Blueteq principal's document regarding set templates to the group to review.	[REDACTED]		Update 6/2/20 - To discuss under RMOC agenda item
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

BNSSG Area Prescribing Medicines Optimisation Committee (APMOC) - Action Log



Meeting Date & Item No.	Ref.	Action Point	Owner	Timescale	Update/Comments	Status
Actions from 20th June 2019 Meeting						
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
Actions from 5th December 2019 Meeting						
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
Actions from 6th February 2020 meeting						
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]

S-Medical
Directorate CE
Shared Area

Open Actions

06/02/2020	187	<p>RMOC - Hydroxychloroquine There has been some publish guidelines that has gone on the SPS website. Hydroxychloroquine guideline, FOC, BlueTeq and Sequential use Biologics asked the Medicines, Quality and Safety group to pick up Hydroxychloroquine guideline and potentially look at doing a pathway which we can then be brought back to APMOC to update.</p>	[REDACTED]	5/6/2020 - work has been on hold due to COVID, to discuss next steps at meeting	Open
06/02/2020	188	<p>RMOC- Biosimilar insulin's toolkit [REDACTED] discussed that CSU have developed a toolkit regarding Biosimilar insulin's which has have positive feedback. [REDACTED] to have a look into CSU toolkit and feedback to APMOC group at next meeting.</p>	[REDACTED]	Update 5/6/2020-Work has been on hold, [REDACTED] to discuss with Diabetes STP grp	Open
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
Actions from Thursday 2nd April 2020 (COVID-19)					
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Closed Actions

19-Sep-18	23	<p><u>RMOC Update</u></p> <p>will circulate agenda for latest meeting electronically when available. All to give feedback to to take forward to next meeting.</p>	/All	21-Nov-18	On agenda for discussion at this meeting 21 st November 2019	Close
19-Sep-18	28	<p>Homely remedies Guidelines - The Author to liaise with</p>		21-Nov-18	<p>in RMOC</p> <p>Homely Remedies Guidelines that came out, so discussion was to look at this in more detail. It was agreed to close this action, but to open a new action to review both Guidelines and work out if we want to change what we have</p>	Close
19-Sep-18	33	<p><u>Self-Care National Guidance & Local Implementation</u> - to share any information with the Group at the next RMOC Meeting in January 2019.</p>		January		Close
19-Sep-18	36	<p><u>AOB - RMOC Free of Charge Guidelines/Policy</u> - All Trust Members to let know if any issues re: adopting RMOC policy.</p>	All		<p>Email sent to to asked if adopted and if any issues - asked for response by 18th Jan 19.</p>	Close

Closed Actions

[REDACTED]	■	[REDACTED]	-		[REDACTED]	-
[REDACTED]	■	[REDACTED]	-		[REDACTED]	-
[REDACTED]	■	[REDACTED]	-		[REDACTED]	-
[REDACTED]	■	[REDACTED]	+		[REDACTED]	-
[REDACTED]	■	[REDACTED]	-		[REDACTED]	-
[REDACTED]	■	[REDACTED]	-		[REDACTED]	-
[REDACTED]	■	[REDACTED]	-		[REDACTED]	-
[REDACTED]	■	[REDACTED]	-		[REDACTED]	-
[REDACTED]	■	[REDACTED]	-		[REDACTED]	-
[REDACTED]	■	[REDACTED]	-		[REDACTED]	-
[REDACTED]	■	[REDACTED]	-		[REDACTED]	-
[REDACTED]	■	[REDACTED]	-		[REDACTED]	-
[REDACTED]	■	[REDACTED]	-		[REDACTED]	-
[REDACTED]	■	[REDACTED]	-		[REDACTED]	-
[REDACTED]	■	[REDACTED]	-		[REDACTED]	-
[REDACTED]	■	[REDACTED]	-		[REDACTED]	-
[REDACTED]	■	[REDACTED]	-		[REDACTED]	-
[REDACTED]	■	[REDACTED]	-		[REDACTED]	-
[REDACTED]	■	[REDACTED]	-		[REDACTED]	-
[REDACTED]	■	[REDACTED]	+		[REDACTED]	-
[REDACTED]	■	[REDACTED]	-		[REDACTED]	-

Closed Actions

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
10/04/2019 Item 8	97	RMOC update to circulate to the group the Liothyronine final documents when available.	[REDACTED]	[REDACTED]	Update 20 June 2019 [REDACTED] advised this was still not available, but she would share with the group when she is able to. Update 15 Aug 2019 - on Agenda to discuss at this meeting.	Close
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Closed Actions

[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
15/08/2019 Item 7 - Guidance - Prescribing of Liothyronine	145	Guidance - Prescribing of Liothyronine and Pathways [Redacted] to provide the name of their respective endocrinologist, together with contact details, to enable to facilitate a meeting for them to discuss this through	[Redacted]	[Redacted]	Update 28Aug2019 - [Redacted] has sent a chase reminder email, to ask for respective endocrinologists from the 3 Trusts, to allow a meeting to be facilitated.	Recommend to Close
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
15/08/2019 Item 7 - Guidance - Prescribing of Liothyronine	146	Guidance - Prescribing of Liothyronine and Pathways Admin to set up a meeting with the endocrinologists from the 3 Trusts, to agree pathways. Meeting to include [Redacted] from the CCG. It was suggested to invite [Redacted]. This meeting to be set up before the next APMOC meeting in December 2019	Admin	[Redacted]	Update 20Oct2019 - Admin has emailed the 3 x endocrinologists to try to arrange a meeting re: Prescribing of Liothyronine and Pathways Invite [Redacted] - starting criteria and stopping criteria. Update November - Guidance of Prescribing of	Closed
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
17/10/2019 Item 6	160	RMOC Update [Redacted] to check with ophthalmologists what the process of retinal or diabetic retinal screening is	[Redacted]	[Redacted]	Update December- It was confirmed that Ophthalmologists are unable to complete retinal or diabetic retinal screening. The group agreed this action can be closed.	Closed

Closed Actions

[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
19-Sep-18	33	<i>Self-Care National Guidance & Local Implementation</i> - [Redacted] to share any information with the Group at the next RMOC Meeting in January 2019.	[Redacted]	January		Close
19-Sep-18	36	<i>AOB - RMOC Free of Charge Guidelines/Policy</i> - All Trust Members to let [Redacted] know if any issues re: adopting RMOC policy.	All [Redacted]		Email sent to [Redacted] to asked if adopted and if any issues - asked for response by 18th Jan 19.	Close
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
21-Nov-2018 Item 8	55	<i>RMOC Update</i> : Liothyronine Guidelines: It was discussed and agreed that these guidelines would be shared with the endocrinologists across all 3 Trusts for their comments. Feedback asap	[Redacted]			Close
21-Nov-2018 Item 8	56	<i>RMOC Update</i> : Liothyronine Guidelines: [Redacted] to search if any on Liothyronine in Primary Care for depression	[Redacted]		Completed - data sent by [Redacted] - on the agenda.	Close
21-Nov-2018 Item 8	57	<i>RMOC Update</i> : Liothyronine Guidelines: [Redacted] to search total number of patients on monotherapy and duel therapy and feed back to acute colleagues.	[Redacted]		Completed - data sent by [Redacted] - on the agenda.	Close
21-Nov-2018 Item 8	58	<i>RMOC Update</i> : Acute Trust Leads to share proposals with endocrinologists asap and feedback	Acute Trust Leads		Update 2-Jan-2019 - [Redacted] advised this action can now be closed	Close
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]		[Redacted]	[Redacted]

Closed Actions

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
10/04/2019 Item 8	97	RMOC update [REDACTED] to circulate to the group the Liothyronine final documents when available.	[REDACTED]	[REDACTED]	Update 20June2019 - [REDACTED] advised this was still not available, but she would share with the group when she is able to. Update 15Aug2019 - on Agenda to discuss at this meeting.	Close
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Closed Actions

[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]

[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
------------	---	------------	------------	--	------------	------------

15/08/2019 Item 7 - Guidance - Prescribing of Liothyronine	145	Guidance - Prescribing of Liothyronine and Pathways to provide the name of their respective endocrinologist, together with contact details, to enable to facilitate a meeting for them to discuss this through	[REDACTED]		Update 28Aug2019. [REDACTED] has sent a chase reminder email, to ask for respective endocrinologists from the 3 Trusts, to allow a meeting to be facilitated.	Recommend to Close
---	-----	---	------------	--	---	-----------------------

[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]

[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]

[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
------------	---	------------	------------	--	------------	------------

[REDACTED]	■	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
------------	---	------------	------------	--	------------	------------

BNSSG Area Prescribing Medicines Optimisation Committee (APMOC)

Date: Thursday 15th October
Time: 13:30-15:30
Location: Virtual- MS TEAMS

Agenda

1	[REDACTED]	[REDACTED]	[REDACTED]
2	Declarations of Interest	Verbal	All
3	[REDACTED]	[REDACTED]	[REDACTED]
4	[REDACTED]	[REDACTED]	[REDACTED]
5	[REDACTED]	[REDACTED]	[REDACTED]
Decision			
6	Guidelines & Pathways Guideline Tracker – future guidelines to update	To be presented at meeting	AD/RM
7	[REDACTED]	[REDACTED]	[REDACTED]
8	[REDACTED]	[REDACTED]	[REDACTED]



■	████████████████████	██████	■
■	████████████████████	██████	■
■	██████████ 	██████	■
■	████████████████████	██████	■
■	████████████████████	██████	██████
■	██████████	██████	■
■	████████████████████	██████	■
	████████████████████	██████	■
	████████████████████	██████	■
	████████████████████ ████████████████████	██████	■
	██████████	██████	■
6.14	Prescribing of Liothyronine- Local Guidance https://www.sps.nhs.uk/wp-content/uploads/2018/11/RMOC-Liothyronine-Guidance-v2.0-final.pdf	Discussion See Link	██████
Strategic			
7	RMOC – Update		



	<ul style="list-style-type: none"> ➤ Lipid pathways-above ➤ Metabolic formulary 	Attached Attached	█
█	█ <ul style="list-style-type: none"> █ █ █ █ 	█ █	█ █
█	█ <ul style="list-style-type: none"> █ █ █ █ █ █ 	█ █	█ █
█	█ <ul style="list-style-type: none"> █ █ █ █ 	█ █	█ █
█	█ <ul style="list-style-type: none"> █ █ 	█	█
█	█ <ul style="list-style-type: none"> █ █ █ █ 	█ █	█ █
Finance/ Value			
█	█ <ul style="list-style-type: none"> █ █ █ █ 	█ █	█ █
Other			
Standing Items			
█	█ <ul style="list-style-type: none"> █ █ 		
	<ul style="list-style-type: none"> █ █ https://www.nice.org.uk/guidance/ng182		





BNSSG Area Prescribing Medicines Optimisation Committee (APMOC)

Minutes of the meeting held on Thursday 15th October.

Time: 1330-1530
Location: MS TEAMS

Minutes

Present		
[REDACTED]	Deputy Director (Medicines Optimisation) BNSSG CCG (<i>chair</i>)	■
[REDACTED]	Urgent Care Clinical Lead, BNSSG CCG	■
[REDACTED]	Interface Pharmacist, BNSSG CCG	■
[REDACTED]-left 1500	Lead Pharmacist-UHBW-Weston	■
[REDACTED]	Principal Medicines Optimisation Pharmacist, BNSSG CCG	■
[REDACTED]	Director of Pharmacy, NBT	■
[REDACTED]	Principal Medicines Optimisation Pharmacist, BNSSG CCG	■
[REDACTED]	Medicines Optimisation Pharmacist, AWP	■
[REDACTED]	Medicines Optimisation Pharmacist, BNSSG CCG (Guest)	■
[REDACTED]	Medicines Optimisation Pharmacist, BNSSG CCG (Guest)	■
[REDACTED]	Team Administrator, BNSSG CCG (Minutes)	■
[REDACTED]	Head of Medicines Optimisation, Sirona Care & Health	■
[REDACTED]	Principal Medicines Optimisation Pharmacist, BNSSG CCG	■
[REDACTED]	Principal Medicines Optimisation Pharmacist, BNSSG CCG	■
[REDACTED]	GP, Prescribing Lead, BNSSG CCG	■
[REDACTED]	Medicines Optimisation Pharmacist, BNSSG CCG Respiratory Specialist Pharmacist, NBT	■
[REDACTED] Joined 1330-1400	UHBW consultant Biochemist	■
[REDACTED]	Medicines Optimisation Pharmacist, BNSSG CCG	■
[REDACTED] 1430- 1500	Medicines Optimisation Senior Pharmacy Technician, BNSSG CCG	■
Apologies		
[REDACTED]	Principal Medicines Optimisation Pharmacist, BNSSG CCG	■
[REDACTED]	Senior Clinical Pharmacist, Air Balloon Surgery	■
[REDACTED]	Lay Member Volunteer - Health Watch North Somerset	■
[REDACTED]	Public Health Consultant, Bristol City Council	■

Item	Action
1 [REDACTED]	



	Item	Action
	[Redacted]	
2	Declarations of Interest No conflicts of interest were identified.	
■	[Redacted]	
4	Action Log [Redacted] [Redacted] [Redacted] [Redacted] Action 188 - RMOC- Biosimilar insulin's toolkit – Action Ongoing [Redacted] [Redacted] [Redacted] [Redacted] [Redacted] [Redacted] [Redacted] [Redacted] [Redacted] [Redacted] [Redacted] [Redacted] [Redacted] [Redacted] [Redacted] [Redacted] [Redacted]	
■	[Redacted]	



	Item	Action
Decision		
6	Guidelines & Pathways Guideline Tracker	
■	[Redacted text]	
■	[Redacted text]	■



	Item	Action
	<ul style="list-style-type: none"> <li data-bbox="210 309 231 338">■ <li data-bbox="263 309 1260 371">[REDACTED] 	<ul style="list-style-type: none"> <li data-bbox="1321 309 1437 331">■ <li data-bbox="1321 344 1453 371">■
<ul style="list-style-type: none"> <li data-bbox="84 421 126 450">■ 	<ul style="list-style-type: none"> <li data-bbox="164 421 509 450">[REDACTED] <li data-bbox="164 488 1161 517">[REDACTED] <li data-bbox="164 526 1182 555">[REDACTED] <li data-bbox="164 564 1257 593">[REDACTED] <li data-bbox="164 602 1225 631">[REDACTED] <li data-bbox="164 640 1189 669">[REDACTED] <li data-bbox="164 678 1275 707">[REDACTED] <li data-bbox="164 716 1265 745">[REDACTED] <li data-bbox="164 754 657 784">[REDACTED] <li data-bbox="164 840 494 869">[REDACTED] <li data-bbox="210 907 231 936">■ <li data-bbox="263 907 1062 936">[REDACTED] 	<ul style="list-style-type: none"> <li data-bbox="1366 907 1412 936">■
<ul style="list-style-type: none"> <li data-bbox="84 987 126 1016">■ 	<ul style="list-style-type: none"> <li data-bbox="164 987 518 1016">[REDACTED] <li data-bbox="164 1055 1252 1084">[REDACTED] <li data-bbox="164 1093 1209 1122">[REDACTED] <li data-bbox="164 1131 1265 1160">[REDACTED] <li data-bbox="164 1169 1145 1198">[REDACTED] <li data-bbox="164 1207 1228 1236">[REDACTED] <li data-bbox="164 1245 1265 1274">[REDACTED] <li data-bbox="164 1283 815 1312">[REDACTED] <li data-bbox="210 1335 231 1364">■ <li data-bbox="263 1335 1201 1364">[REDACTED] <li data-bbox="263 1373 1249 1402">[REDACTED] <li data-bbox="263 1411 1193 1440">[REDACTED] <li data-bbox="263 1449 1272 1478">[REDACTED] <li data-bbox="263 1487 1275 1516">[REDACTED] <li data-bbox="263 1525 1241 1554">[REDACTED] <li data-bbox="263 1563 635 1592">[REDACTED] <li data-bbox="210 1655 231 1684">■ <li data-bbox="263 1655 1272 1684">[REDACTED] <li data-bbox="263 1693 1249 1722">[REDACTED] <li data-bbox="263 1731 1268 1760">[REDACTED] <li data-bbox="263 1769 1058 1798">[REDACTED] <li data-bbox="210 1827 231 1856">■ <li data-bbox="263 1827 1204 1856">[REDACTED] <li data-bbox="263 1865 1262 1895">[REDACTED] <li data-bbox="263 1904 1160 1933">[REDACTED] <li data-bbox="210 1973 231 2002">■ <li data-bbox="263 1973 1249 2002">[REDACTED] <li data-bbox="263 2011 1272 2040">[REDACTED] 	



	Item	Action
	<p>[Redacted]</p> <ul style="list-style-type: none"> ■ [Redacted] ■ [Redacted] ■ [Redacted] ■ [Redacted] ■ [Redacted] ■ [Redacted] 	<p>[Redacted]</p> <p>[Redacted]</p>
<ul style="list-style-type: none"> ■ [Redacted] 	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	<p>[Redacted]</p>

	Item	Action
	<p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED][REDACTED][REDACTED][REDACTED]	<ul style="list-style-type: none">■■■■
■	<p>[REDACTED]</p>	

	Item	Action
	<p>[Redacted text]</p> <ul style="list-style-type: none">[Redacted text][Redacted text]	<ul style="list-style-type: none">[Redacted text][Redacted text]
<ul style="list-style-type: none">[Redacted text]	<p>[Redacted text]</p> <ul style="list-style-type: none">[Redacted text][Redacted text][Redacted text]	<ul style="list-style-type: none">[Redacted text][Redacted text][Redacted text]

	Item	Action
	<ul style="list-style-type: none"> [REDACTED] 	<ul style="list-style-type: none"> ■
<ul style="list-style-type: none"> ■ 	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] 	<ul style="list-style-type: none"> ■
<ul style="list-style-type: none"> ■ 	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	
<ul style="list-style-type: none"> ■ 	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] 	<ul style="list-style-type: none"> ■
<ul style="list-style-type: none"> ■ 	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	

	Item	Action
	<p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] 	<p>■</p>
6.14	<p>Prescribing of Liothyronine- Local Guidance https://www.sps.nhs.uk/wp-content/uploads/2018/11/RMOC-Liothyronine-Guidance-v2.0-final.pdf</p> <p>■ stated to the group that have still not managed to have a system wide process in place around prescribing and assessing patients for Liothyronine, but discussion will be taking place with clinicians across the trusts to get an agreed pathway.</p>	
Strategic		
7	<p>RMOC – Update</p> <ul style="list-style-type: none"> ➢ Lipid pathways-above ➢ Metabolic formulary <p>■ asked ■ to take the Metabolic Formulary to the Formulary group to see if members are happy to adopt and for local systems to use.</p> <ul style="list-style-type: none"> • ACTION 243: ■ to discuss Metabolic Formulary within the Formulary group and feedback. 	<p>■</p>
■	<p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	



	Item	Action
■	<p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	
■	<p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] 	■
■	<p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	

	Item	Action
	<p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] 	<p>■</p>
<p>■</p>	<p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] <p>[REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] 	<p>■</p>
	<p>[REDACTED]</p>	
<p>■</p>	<p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	
	<p>[REDACTED]</p>	
<p>■</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	

Closed Actions

19-Sep-18	33	<i>Self-Care National Guidance & Local Implementation</i> - to share any information with the Group at the next RMOG Meeting in January 2019.		January		Close
19-Sep-18	36	<i>AOB - RMOG Free of Charge Guidelines/Policy</i> - All Trust Members to let know if any issues re: adopting RMOG policy.	All		Email sent to to asked if adopted and if any issues - asked for response by 18th Jan 19.	Close
21						
21-Nov-2018 Item 8	55	<i>RMOC Update</i> : Liothyronine Guidelines: It was discussed and agreed that these guidelines would be shared with the endocrinologists across all 3 Trusts for their comments. Feedback asap				Close
21-Nov-2018 Item 8	56	<i>RMOC Update</i> : Liothyronine Guidelines: to search if any on Liothyronine in Primary Care for depression			Completed - data sent by - on the agenda.	Close
21-Nov-2018 Item 8	57	<i>RMOC Update</i> : Liothyronine Guidelines: to search total number of patients on monotherapy and dual therapy and feed back to acute colleagues.			Completed - data sent by - on the agenda.	Close
21-Nov-2018 Item 8	58	<i>RMOC Update</i> : Acute Trust Leads to share proposals with endocrinologists asap and feedback	Acute Trust Leads		Update 2-Jan-2019 - advised this action can now be closed	Close

Closed Actions

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
10/04/2019 Item 8	97	RMOC update [REDACTED] to circulate to the group the Liothyronine final documents when available.	[REDACTED]	[REDACTED]	Update 20June2019 - [REDACTED] advised this was still not available, but she would share with the group when she is able to. Update 15Aug2019 - on Agenda to discuss at this meeting.	Close
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Closed Actions

[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-

[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	-

[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	-

[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	-

[REDACTED]	-	[REDACTED]	+	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	+	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-

Closed Actions

[Redacted]	■	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	■	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	■	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	■	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	■	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	■	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	■	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	■	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	■	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	■	[Redacted]	[Redacted]		[Redacted]	[Redacted]

[Redacted]	■	[Redacted]	[Redacted]		[Redacted]	[Redacted]
------------	---	------------	------------	--	------------	------------

15/08/2019 Item 7 - Guidance - Prescribing of Liothyronine	145	Guidance - Prescribing of Liothyronine and Pathways [Redacted] to provide the name of their respective endocrinologist, together with contact details, to enable to facilitate a meeting for them to discuss this through	[Redacted]		Update 28Aug2019. [Redacted] has sent a chase reminder email, to ask for respective endocrinologists from the 3 Trusts, to allow a meeting to be facilitated.	Recommend to Close
---	-----	--	------------	--	---	-----------------------

[Redacted]	■	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	■	[Redacted]	[Redacted]		[Redacted]	[Redacted]

[Redacted]	■	[Redacted]	[Redacted]		[Redacted]	[Redacted]
[Redacted]	■	[Redacted]	[Redacted]		[Redacted]	[Redacted]

[Redacted]	■	[Redacted]	[Redacted]		[Redacted]	[Redacted]
------------	---	------------	------------	--	------------	------------

[Redacted]	■	[Redacted]	[Redacted]		[Redacted]	[Redacted]
------------	---	------------	------------	--	------------	------------

Closed Actions

19-Sep-18	33	Self-Care National Guidance & Local Implementation - to share any information with the Group at the next RMOC Meeting in January 2019.		January		Close
19-Sep-18	36	AOB - RMOC Free of Charge Guidelines/Policy - All Trust Members to let know if any issues re: adopting RMOC policy.	All		Email sent to to asked if adopted and if any issues - asked for response by 18th Jan 19.	Close
21-Nov-2018 Item 8	55	RMOC Update : Liothyronine Guidelines: It was discussed and agreed that these guidelines would be shared with the endocrinologists across all 3 Trusts for their comments. Feedback asap				Close
21-Nov-2018 Item 8	56	RMOC Update : Liothyronine Guidelines: to search if any on Liothyronine in Primary Care for depression			Completed - data sent by - on the agenda.	Close
21-Nov-2018 Item 8	57	RMOC Update : Liothyronine Guidelines: to search total number of patients on monotherapy and dual therapy and feed back to acute colleagues.			Completed - data sent by - on the agenda.	Close
21-Nov-2018 Item 8	58	RMOC Update: Acute Trust Leads to share proposals with endocrinologists asap and feedback	Acute Trust Leads		Update 2-Jan-2019 - advised this action can now be closed	Close

Closed Actions

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
10/04/2019 Item 8	97	RMOC update [REDACTED] to circulate to the group the Liothyronine final documents when available.	[REDACTED]	[REDACTED]	Update 20June2019 - [REDACTED] advised this was still not available, but she would share with the group when she is able to. Update 15Aug2019 - on Agenda to discuss at this meeting.	Close
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Closed Actions

[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-

[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	-

[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	-

[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	-

[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-

Closed Actions

[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]

[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
------------	---	------------	------------	--	------------	------------

15/08/2019 Item 7 - Guidance - Prescribing of Liothyronine	145	Guidance - Prescribing of Liothyronine and Pathways [REDACTED] to provide the name of their respective endocrinologist, together with contact details, to enable to facilitate a meeting for them to discuss this through	[REDACTED]		Update 28Aug2019. [REDACTED] has sent a chase reminder email, to ask for respective endocrinologists from the 3 Trusts, to allow a meeting to be facilitated.	Recommend to Close
---	-----	--	------------	--	---	-----------------------

[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]

[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]

[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
------------	---	------------	------------	--	------------	------------

[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
------------	---	------------	------------	--	------------	------------

-	-	[REDACTED]	-	-	[REDACTED]	-
-	-	[REDACTED]	-	-	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	-	[REDACTED]	-
-	-	[REDACTED]	-	-	[REDACTED]	-
-	-	[REDACTED]	-	-	[REDACTED]	-
-	-	[REDACTED]	-	-	[REDACTED]	-
-	-	[REDACTED]	-	-	[REDACTED]	-
-	-	[REDACTED]	-	-	[REDACTED]	-
-	-	[REDACTED]	-	-	[REDACTED]	-
-	-	[REDACTED]	-	-	[REDACTED]	-
-	-	[REDACTED]	-	-	[REDACTED]	-
-	-	[REDACTED]	-	-	[REDACTED]	-
-	-	[REDACTED]	-	-	[REDACTED]	-
-	-	[REDACTED]	-	-	[REDACTED]	-
-	-	[REDACTED]	-	-	[REDACTED]	-
-	-	[REDACTED]	-	-	[REDACTED]	-

Closed Actions

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
10/04/2019 Item 8	97	RMOC update [REDACTED] to circulate to the group the Liothyronine final documents when available.	[REDACTED]	[REDACTED]	Update 20June2019 - [REDACTED] advised this was still not available, but she would share with the group when she is able to. Update 15Aug2019 - on Agenda to discuss at this meeting.	Close
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Closed Actions

[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]

[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
------------	---	------------	------------	--	------------	------------

15/08/2019 Item 7 - Guidance - Prescribing of Liothyronine	145	Guidance - Prescribing of Liothyronine and Pathways [REDACTED] to provide the name of their respective endocrinologist, together with contact details, to enable to facilitate a meeting for them to discuss this through	[REDACTED]		Update 28Aug2019. [REDACTED] has sent a chase reminder email, to ask for respective endocrinologists from the 3 Trusts, to allow a meeting to be facilitated.	Recommend to Close
---	-----	--	------------	--	---	-----------------------

[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]

[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]

[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
------------	---	------------	------------	--	------------	------------

[REDACTED]	-	[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
------------	---	------------	------------	--	------------	------------

-	-	[REDACTED]	-	-	[REDACTED]	-
-	-	[REDACTED]	-	-	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+

Closed Actions

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
10/04/2019 Item 8	97	RMOC update [REDACTED] to circulate to the group the Liothyronine final documents when available.	[REDACTED]	[REDACTED]	Update 20June2019 - [REDACTED] advised this was still not available, but she would share with the group when she is able to. Update 15Aug2019 - on Agenda to discuss at this meeting.	Close
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Closed Actions

[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-

[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	-

[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	-

[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	-

[REDACTED]	-	[REDACTED]	+	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	+	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	[REDACTED]	[REDACTED]	-

-	-	[REDACTED]	-	-	[REDACTED]	-
-	-	[REDACTED]	-	-	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+

Closed Actions

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
10/04/2019 Item 8	97	RMOC update [REDACTED] to circulate to the group the Liothyronine final documents when available.	[REDACTED]	[REDACTED]	Update 20June2019 - [REDACTED] advised this was still not available, but she would share with the group when she is able to. Update 15Aug2019 - on Agenda to discuss at this meeting.	Close
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Closed Actions

[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
------------	---	------------	------------	------------	------------	------------

15/08/2019 Item 7 - Guidance - Prescribing of Liothyronine	145	Guidance - Prescribing of Liothyronine and Pathways [REDACTED] to provide the name of their respective endocrinologist, together with contact details, to enable SLC to facilitate a meeting for them to discuss this through	[REDACTED]	[REDACTED]	Update 28Aug2019. [REDACTED] has sent a chase reminder email, to ask for respective endocrinologists from the 3 Trusts, to allow a meeting to be facilitated.	Recommend to Close
---	-----	--	------------	------------	---	-----------------------

[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
------------	---	------------	------------	------------	------------	------------

[REDACTED]	-	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
------------	---	------------	------------	------------	------------	------------

-	-	[REDACTED]	-	-	[REDACTED]	-
-	-	[REDACTED]	-	-	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+

Closed Actions

[REDACTED]		[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]		[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
		[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	■	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	■	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	■	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	■	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	■	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	■	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	■	[REDACTED]	[REDACTED]
19-Sep-18	23	<u>RMOC Update</u> [REDACTED] will circulate agenda for latest meeting electronically when available. All to give feedback to [REDACTED] to take forward to next meeting.	[REDACTED] /All	21-Nov-18	On agenda for discussion at this meeting 21 st November 2019	Close
[REDACTED]	■	[REDACTED]	[REDACTED]	■	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	■	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	■	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	■	[REDACTED]	[REDACTED]
19-Sep-18	28	Homely remedies Guidelines - The Author ([REDACTED]) to liaise with [REDACTED]	■	21-Nov-18	[REDACTED] provided an update and stated that there was an RMOC Homely Remedies Guidelines that came out, so discussion was to look at this in more detail. It was agreed to close this action, but to open a new action to review both Guidelines and work out if we want to change what we have	Close
[REDACTED]	■	[REDACTED]	■	■	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	■	■	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	■	[REDACTED]	[REDACTED]

Closed Actions

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
10/04/2019 Item 8	97	RMOC update [REDACTED] to circulate to the group the Liothyronine final documents when available.	[REDACTED]	[REDACTED]	Update 20June2019 - [REDACTED] advised this was still not available, but she would share with the group when she is able to. Update 15Aug2019 - on Agenda to discuss at this meeting.	Close
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	■	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

-	-	[REDACTED]	-	-	[REDACTED]	-
-	-	[REDACTED]	-	-	[REDACTED]	-
[REDACTED]	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+
-	-	[REDACTED]	-	-	[REDACTED]	+

From:
To:



Subject: RE: Liothyronine
Date: 28 July 2019 15:59:45
Attachments: [image001.png](#)
[image002.jpg](#)
[image003.png](#)

I've just read the RMOG guidance on T3 in conjunction with the NHSE guidance which can be found on page 25 here

<https://www.england.nhs.uk/wp-content/uploads/2017/11/items-which-should-not-be-routinely-prescribed-in-pc-ccg-guidance-v2.pdf>

Both NHSE and RMOG advise there may be a small cohort of patients who may need ongoing T2 in combination with T4, but these patients should all be assessed by an endocrinologist and have a 3 month trial (either on it if they are T3 naive or off it if they are already taking it)

The RMOG guidance goes one step further and advises this small cohort of patients be on a shared care agreement with primary care, after 3 months.

█ - I'm not sure where we stand with the need to adhere to RMOG guidance. My personal opinion is that keeping T3 as red would be a deterrent against over use of this expensive, non-evidence based medication and consultants would be far less likely to go down this route if they have to arrange all the repeat prescribing. Whereas if it's amber shared care, it is too easy to just start it and continue prescribing indefinitely in primary care.

What is conspicuous by its absence is the fact that there is no guidance on either document for how consultants are supposed to assess a patient's need for T3. There are many euthyroid patients out there whose tiredness/fatigue interferes with their ADL and the majority have a psychological origin.

I will not be at APMOC but if we cannot deviate from RMOG, then we have no choice but to change T4 in formulary to amber 3 months. Can catch up with you about this on Tues





From: [Redacted]

Sent: 22 July 2019 12:02

To: [Redacted]

Subject: Liothyronine and Adalaimumab RMOc Publications

Dear All

The following documents have been published in July and are available on the SPS website:

- Updated RMOc Liothyronine Guidance: <https://www.sps.nhs.uk/articles/updated-rmoc-guidance-prescribing-of-liothyronine/>
- [Redacted]

Please feel free to distribute within your networks.

Kind regards

[Redacted]

[Redacted]

Practice Pharmacist & Independent Prescriber – NHS Bristol CCG

[Redacted]





The information in this email, including any attachments, is confidential and is intended for the attention and use of the named addressee(s). It must not be disclosed to any other person(s) without our permission.